通过4例炎性乳腺癌新辅助放疗病例及文献复习，分析探讨炎性乳腺癌新辅助放疗的可行性。

回顾性分析4例临床分期为T_4dN_1~3M₀的炎性乳腺癌患者，新辅助全身治疗失败后加用新辅助放疗，观察其疗效，并回顾分析相关文献。

4例炎性乳腺癌患者新辅助放疗后均获得临床缓解，成功进行乳腺癌改良根治术。术后无严重并发症，手术切口愈合良好，无坏死。1例患者术后病理完全缓解，3例部分缓解。中位随访时间26个月（18~103个月），1例胸壁复发，2例肺、纵隔淋巴结转移，1例无复发转移。1例死亡（肺转移）。

精确放射治疗技术对新辅助全身治疗失败的炎性乳腺癌患者进行新辅助放疗，安全有效。

To analyze the feasibility of neoadjuvant radiotherapy for inflammatory breast cancer by reviewing four cases and performed a literature review.

Four patients with inflammatory breast cancer (clinical stage T_4dN_1-3M₀) were treated with neoadjuvant radiotherapy after the failure of neoadjuvant systemic therapy, and the curative effect was observed. A review of the relevant literature was performed.

All the four patients with inflammatory breast cancer achieved clinical remission after neoadjuvant radiotherapy, and modified radical mastectomy was performed successfully. There were no serious complications after operation, and the incision healed well and there was no necrosis. Postoperative complete pathological remission was achieved in one case and partial remission in three. The median follow-up period was 26 months (18-103 months). One case developed chest wall recurrence, two developed lung and mediastinal lymph node metastasis, and one had no recurrence or metastasis. One case died of lung metastasis.

With the progress of radiotherapy technology, neoadjuvant radiotherapy can be considered as a safe and effective alternative treatment for inflammatory breast cancer patients when neoadjuvant systemic therapy failed.